ONCOSEC™

ARMING THE IMMUNE SYSTEM TO FIGHT CANCER

The ImmunoPulse® platform is a powerful proprietary OncoSec technology for delivering DNA-based therapeutics directly into tumor cells. Clinical studies to date have focused on the intratumoral delivery of DNA expressing interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. These studies have demonstrated up to 48% response in advanced melanoma patients predicted to be non-responsive to anti-PD-1 therapies, a population with very few options for treatment. Clinical response and translational immune profiling data position OncoSec to expand into multiple indications with the potential to address this great unmet medical need. We believe that our technology has the promise to change the way cancers are treated, and how new drugs are discovered; all while potentially improving safety and increasing the scale and speed of development at a lower cost to the patient not seen in today's industry.

Recent Highlights

- Interim Phase II clinical trial data show 48% best overall response rates from the combination of ImmunoPulse® IL-12 with KEYTRUDA® in advanced melanoma patients predicted to be non-responsive to KEYTRUDA® alone.
- FDA fast-track designation positions ImmunoPulse® IL-12 as the first therapeutic approved for patients who fail anti-PD-1 therapies in melanoma, a projected billion-dollar market opportunity.
- The introduction of GENESIS™ with proprietary TRACE™ (Tissue-Based Real-Time Adaptive Control Electroporation) technology is a revolutionary approach to gene electrotransfer: the ability to safely and consistently deliver complex DNA-encoded therapeutics across heterogeneous tissues through tissue-responsive control of the electrical pulse.
- The launch of our Technology Access Program (TAP) and rapid execution of two diverse TAP agreements is demonstrating applicability of OncoSec technologies to meet a wide variety of preclinical objectives.

2017 Key Milestones

- ✓ Data announcement at key scientific meeting from ongoing clinical program in predicted anti-PD-1 non-responder population in advanced melanoma
- ✓ Regulatory Update on status of discussions with the FDA regarding ImmunoPulse IL-12 clinical development strategy
- Finalization of drug supply partnership and initiation of ImmunoPulse® IL-12 registration-directed trial in combination with anti-PD-1 in stage III/ IV melanoma patients who are progressing on KEYTRUDA® or OPDIVO® alone
- Initiation of "PISCES" registration-directed trial in stage III/IV melanoma anti-PD-1 non-responder population
- Announcement of key collaborations and technology access program (TAP) agreements using TRACE™- enabled GENESIS™ delivery technology
- Completion of pre-IND studies for next OncoSec clinical candidate in preparation for 2018 filing and advancement to first-in-human
- Announcement of preclinical pipeline and future indications

Stock Overview

Exchange | Symbol	**NASDAQ | ONCS**
Shares Outstanding	**20.8 M**
Market Cap*	**$26.0 M**
Cash, Cash Equivalents and Short-Term Investments*	**$20.5 M**
Cash Runway*	**Q1 2018**
Debt*	**$0**
Analyst Coverage	**H.C. Wainwright Maxim Group Noble Life Science Partners**

Senior Management	Board of Directors
Punit Dhillon Chief Executive Officer	**Avtar Dhillon, M.D.** Chairman
Richard Slansky Chief Financial Officer	**Punit Dhillon**
Sharron Gargosky, Ph.D. Chief Clinical and Regulatory Officer	**James M DeMesa, M.D.** NCGC Chairman
Sheela Mohan-Peterson, JD, MS Chief Legal and Compliance Officer	**Anthony E. Maida, Ph.D.** Audit Committee Chairman

OncoSec Headquarters

5820 Nancy Ridge Drive | San Diego | CA | 92121

p| 855.662.6732 f| 858.430.3832 w|www.OncoSec.com

Investor Relations | 855.662.6732 | investors@oncosec.com
Media Relations | 855.662.6732 | media@oncosec.com
Business Development | 858.230.8780 | bd@oncosec.com

This Corporate Profile contains certain forward-looking statements, as described in the Private Securities Litigation Reform Act of 1995. These include comments concerning clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of OncoSec's technology by potential corporate partners, capital market conditions, timing of events, cash consumption and other subjects. Such statements are subject to factors, risks and uncertainties, such as those described in the Company's periodic SEC filings, that may cause actual results to differ materially from those expressed or implied by such forward looking statements.